General Dermatology
Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Anti-Aging
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management

Comments on the Epsolay FDA Approval for Rosacea

Name: Comments on the Epsolay FDA Approval for Rosacea
Uploaded: 2022-05-02T15:46:00.000Z
Description: Julie Harper, MD, talks about the Epsolay drug approval that happened April 25. She dives into its mechanism of action, its potential as both a first line treatment or combination therapy, and what she would like to see next in its research.

May 2, 2022

Linda Stocum, Associate Editor

Video

Julie Harper, MD, talks about the Epsolay drug approval that happened April 25. She dives into its mechanism of action, its potential as both a first line treatment or combination therapy, and what she would like to see next in its research.

Julie Harper, MD, of the Dermatology and Skin Care Center of Birmingham, Alabama, sits down to talk the approval of the 5% encapsulated benzoyl peroxide (E-BPO) cream (Epsolay; Sol-Gel Technologies Ltd and Galderma) that was just recently approved for the treatment of inflammatory lesions of rosacea (papulopustular rosacea or PPR) in adult patients.

This long awaited drug approval is the first rosacea drug approved this year and Harper talks how it works, its potential as a first line treatment, and much more in this interview.